This Regulation lays down factors to be considered when implementing Article 3 of Regulation (EC) No 141/2000 on orphan medicinal products and establishes definitions of ‘similar medicinal product’ and ‘clinical superiority’ for the purposes of implementing Article 8 of the abovementioned Regulation. It is intended to assist potential sponsors, the Committee for Orphan Medicinal Products, and competent authorities in the interpretation of Regulation (EC) No 141/2000.
Art. 1 Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…
Purpose
In forcesince 19 Jun 2018
Changed on 19 Jun 2018
Purpose
This Regulation lays down factors to be considered when implementing Article 3 of Regulation (EC) No 141/2000 on orphan medicinal products and establishes definitions of "‘similar medicinal product" and "’ and ‘clinical superiority"’ for the purposes of implementing Article 8 of the abovementioned Regulation. It is intended to assist potential sponsors, the Committee for Orphan Medicinal Products, and competent authorities in the interpretation of Regulation (EC) No 141/2000.
- 19 Jun 2018 – todayin force
- 27 Apr 2000 – 19 Jun 2018earlier wording